 |
Company Creates Bioethics Panel on Trial Drugs
New York Times - May 7, 2015
Johnson & Johnson has appointed a nationally known bioethicist to create a panel that will make decisions about patients’ requests for potentially lifesaving medicine, responding to an emotional debate over whether companies should allow desperately ill people to have access to the drugs before they are approved.
Actavis and its Forced Switch Could Cost Medicare $288M This Year: Study
Wall Street Journal - May 7, 2015
If Actavis were allowed to discontinue sales of an older Alzheimer’s pill and steer patients toward a newer version in order to blunt generic competition, the move could cost Medicare Part D as much as $288 million during the last six months of 2015, according to a new government analysis.
Court Blocks Novartis Copy of Amgen Cancer-Care Drug
Wall Street Journal - May 7, 2015
A U.S. appeals court has blocked Novartis AG from selling its knockoff version of an Amgen Inc. cancer supportive-care drug in the U.S. until the court resolves a legal fight between the rivals.
What’s Next If The Supreme Court Strikes Down Obamacare Aid?
Kaiser Health News - May 11, 2015
Millions of Americans get subsidized health insurance under the Affordable Care Act. But those subsidies are being challenged. And in the coming weeks the Supreme Court could rule that in more than 30 states, the subsidies are illegal.
AbbVie Receives Breakthrough Designation for Cancer Drug
Drug Discovery & Development - May 7, 2015
The U.S. Food and Drug Administration has granted breakthrough therapy designation for its leukemia drug, to speed up the regulatory review process.
NABP warns against ordering Rxs online
Drug Toppics - May 5, 2015
The National Association of Boards of Pharmacy (NABP) recently issued a report listing illegal online drug sellers and detailing the threat they pose to the public.
Number of Americans using $100,000 in medicines triples: Express Scripts
Reuters - May 13, 2015
More than a half-million U.S. patients had medication costs in excess of $50,000 in 2014, an increase of 63 percent from the prior year, as doctors prescribed more expensive specialty drugs for diseases such as cancer and hepatitis C, according to an Express Scripts report released on Wednesday.
Drugmaker Sues FDA Over Right to Discuss Off-Label Uses
New York Times - May 7, 2015
Drugmakers have long argued they should have the right to talk to doctors about unapproved uses for their products, as long as they are being truthful. And in some cases, courts have agreed.
Rubella Eliminated From The Americas, Thanks To MMR Vaccine
Forbes - April 30, 2015
First we wiped out smallpox in North and South America. Then we rid the Americas of polio. Now, for the third time, the Americas are the first region in the world to eliminate yet another disease through vaccines: rubella.
Hepatitis C infections soaring, fueled by prescription painkiller abuse
USA TODAY - May 8, 2015
Rates of hepatitis C are soaring, largely driven by an epidemic of prescription painkiller abuse, a new report shows.
Heart Drug Digoxin May Not Be Best for Some Heart Patients
HealthDay News - May 5, 2015
Taking the heart drug digoxin may increase the risk of premature death in patients with an irregular heartbeat and in those suffering from heart failure, German researchers report.
FDA Questions Benefit of Cystic Fibrosis Drug From Vertex
Drug Discovery & Development - May 11, 2015
Federal health regulators have questions about the benefits of an experimental combination drug for cystic fibrosis, including whether the addition of a second drug ingredient adds to the pill's effectiveness.
Contact,
Jan Tankersley
Senior Vice President, Marketing & Sales
Pharmaceutical Strategies Group (PSG)
Office: 972-943-7141
Email: JTankersley@PSGConsults.com
PSGNewsletter@PSGConsults.com
www.PSGConsults.com
 |
 |
 |